placebo) on the primary outcome measure, change from baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Improvement (p ... CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused ...

CervoMed (CRVO) announced that investigators plan to present results ... Improvement on primary outcome measures, change in CDR-SB, with the New Capsules both vs. Old Capsules during first 16 weeks of ...

CervoMed (CRVO) is climbing 3% after Boral Capital upgraded the shares to Buy from Hold. The investment bank placed a $10 ...

CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that investigators plan to present results ...

Shares of NASDAQ CRVO opened at $9.48 on Thursday. The business’s 50 day moving average is $4.00 and its two-hundred day moving average is $7.64. CervoMed has a 52-week low of $1.80 and a 52 ...